A Six-month, Open Labeled, Multi-centered, Observational Study for the Tolerability of Exelon Patch (Rivastigmine) for Patients With Alzheimer's Disease.

Trial Profile

A Six-month, Open Labeled, Multi-centered, Observational Study for the Tolerability of Exelon Patch (Rivastigmine) for Patients With Alzheimer's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms X-MEN
  • Most Recent Events

    • 02 May 2016 Status changed from recruiting to completed.
    • 15 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top